Demircan Tan,B.Turan,T.Yucel,B.Altundag Kara,S.Salman Yilmaz,S.Yildirim,A.Acil Tıp / Emergency Medicine2024-05-252024-05-25202042149-204210.5222/MMJ.2020.587082-s2.0-85087414781https://doi.org/10.5222/MMJ.2020.58708https://hdl.handle.net/20.500.14517/2483Objective: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, bloodbased epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa). Method: A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls. Results: The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localized PCa (p<0.05). Conclusion: Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa. © Istanbul Medeniyet University Faculty of Medicine.eninfo:eu-repo/semantics/openAccessDNA methylationEpigeneticsProstate cancerSOCS3ArticleQ235299105379612